Elicio Therapeutics, Inc.
ELTX
Rank in Stocks
#23275
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to... Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Share Price
$1.59
Last synced: 2026-11-18
Market Cap
$41.80M
Change (1 day)
11.19%
Change (1 year)
-80.10%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Elicio Therapeutics, Inc. (ELTX)
Category
Healthcare
Operating Margin for Elicio Therapeutics, Inc. (ELTX)
Operating Margin as of November 2026 TTM: 0.00%
According to Elicio Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Elicio Therapeutics, Inc. from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | -100.00% |
| 2021 | -138.84% | -92.77% |
| 2020 | -1,919.20% | -26.05% |
| 2019 | -2,595.23% | 629.06% |
| 2018 | -355.97% | 5,793.54% |
| 2013 | -6.04% | 5.23% |
| 2012 | -5.74% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | - |
US
|
|
| 33.87% | - |
US
|
|
| -116.04% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Elicio Therapeutics, Inc.'s operating margin
What was Elicio Therapeutics, Inc.'s operating margin in 2025?
In 2025, Elicio Therapeutics, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Elicio Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Elicio Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2020 (-1,919.20%).
How does Elicio Therapeutics, Inc.'s operating margin compare with similar companies?
Elicio Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.